nL-SAA1-01 for Amyloidosis
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess the safety and efficacy of a subcutaneous injection of nL-SAA1-01in a patient with AA Amyloidosis.
Research Team
NL
Nelson Leung, MD
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for patients with AA Amyloidosis. Specific eligibility details are not provided, but typically participants must meet certain health criteria and may be required to have a confirmed diagnosis of AA Amyloidosis.Inclusion Criteria
Biopsy proven AA amyloidosis
My cancer can be measured by tests.
I can travel to the study location and follow up as required.
Exclusion Criteria
Participant has any condition that in the opinion of the site investigator, would ultimately prevent the completion of study procedures
Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive subcutaneous injection of nL-SAA1-01
1 year
Follow-up
Participants are monitored for safety and effectiveness after treatment
4 weeks
Treatment Details
Interventions
- nL-SAA1-01
Trial Overview The study is testing the safety and effectiveness of nL-SAA1-01, which is administered through an injection under the skin (subcutaneous) to treat AA Amyloidosis.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: nL-SAA1-01Experimental Treatment1 Intervention
Subject will receive subcutaneous injection of nL-SAA1-01
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nelson Leung, MD
Lead Sponsor
Trials
1
Recruited
1+
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.